Cargando…

Costs of care for persons with opioid dependence in commercial integrated health systems

BACKGROUND: When used in general medical practices, buprenorphine is an effective treatment for opioid dependence, yet little is known about how use of buprenorphine affects the utilization and cost of health care in commercial health systems. METHODS: The objective of this retrospective cohort stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Lynch, Frances L, McCarty, Dennis, Mertens, Jennifer, Perrin, Nancy A, Green, Carla A, Parthasarathy, Sujaya, Dickerson, John F, Anderson, Bradley M, Pating, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142137/
https://www.ncbi.nlm.nih.gov/pubmed/25123823
http://dx.doi.org/10.1186/1940-0640-9-16
_version_ 1782331732357283840
author Lynch, Frances L
McCarty, Dennis
Mertens, Jennifer
Perrin, Nancy A
Green, Carla A
Parthasarathy, Sujaya
Dickerson, John F
Anderson, Bradley M
Pating, David
author_facet Lynch, Frances L
McCarty, Dennis
Mertens, Jennifer
Perrin, Nancy A
Green, Carla A
Parthasarathy, Sujaya
Dickerson, John F
Anderson, Bradley M
Pating, David
author_sort Lynch, Frances L
collection PubMed
description BACKGROUND: When used in general medical practices, buprenorphine is an effective treatment for opioid dependence, yet little is known about how use of buprenorphine affects the utilization and cost of health care in commercial health systems. METHODS: The objective of this retrospective cohort study was to examine how buprenorphine affects patterns of medical care, addiction medicine services, and costs from the health system perspective. Individuals with two or more opioid-dependence diagnoses per year, in two large health systems (System A: n = 1836; System B: n = 4204) over the time span 2007–2008 were included. Propensity scores were used to help adjust for group differences. RESULTS: Patients receiving buprenorphine plus addiction counseling had significantly lower total health care costs than patients with little or no addiction treatment (mean health care costs with buprenorphine treatment = $13,578; vs. mean health care costs with no addiction treatment = $31,055; p < .0001), while those receiving buprenorphine plus addiction counseling and those with addiction counseling only did not differ significantly in total health care costs (mean costs with counseling only: $17,017; p = .5897). In comparison to patients receiving buprenorphine plus counseling, those with little or no addiction treatment had significantly greater use of primary care (p < .001), other medical visits (p = .001), and emergency services (p = .020). Patients with counseling only (compared to patients with buprenorphine plus counseling) used less inpatient detoxification (p < .001), and had significantly more PC visits (p = .001), other medical visits (p = .005), and mental health visits (p = .002). CONCLUSIONS: Buprenorphine is a viable alternative to other treatment approaches for opioid dependence in commercial integrated health systems, with total costs of health care similar to abstinence-based counseling. Patients with buprenorphine plus counseling had reduced use of general medical services compared to the alternatives.
format Online
Article
Text
id pubmed-4142137
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41421372014-08-25 Costs of care for persons with opioid dependence in commercial integrated health systems Lynch, Frances L McCarty, Dennis Mertens, Jennifer Perrin, Nancy A Green, Carla A Parthasarathy, Sujaya Dickerson, John F Anderson, Bradley M Pating, David Addict Sci Clin Pract Research BACKGROUND: When used in general medical practices, buprenorphine is an effective treatment for opioid dependence, yet little is known about how use of buprenorphine affects the utilization and cost of health care in commercial health systems. METHODS: The objective of this retrospective cohort study was to examine how buprenorphine affects patterns of medical care, addiction medicine services, and costs from the health system perspective. Individuals with two or more opioid-dependence diagnoses per year, in two large health systems (System A: n = 1836; System B: n = 4204) over the time span 2007–2008 were included. Propensity scores were used to help adjust for group differences. RESULTS: Patients receiving buprenorphine plus addiction counseling had significantly lower total health care costs than patients with little or no addiction treatment (mean health care costs with buprenorphine treatment = $13,578; vs. mean health care costs with no addiction treatment = $31,055; p < .0001), while those receiving buprenorphine plus addiction counseling and those with addiction counseling only did not differ significantly in total health care costs (mean costs with counseling only: $17,017; p = .5897). In comparison to patients receiving buprenorphine plus counseling, those with little or no addiction treatment had significantly greater use of primary care (p < .001), other medical visits (p = .001), and emergency services (p = .020). Patients with counseling only (compared to patients with buprenorphine plus counseling) used less inpatient detoxification (p < .001), and had significantly more PC visits (p = .001), other medical visits (p = .005), and mental health visits (p = .002). CONCLUSIONS: Buprenorphine is a viable alternative to other treatment approaches for opioid dependence in commercial integrated health systems, with total costs of health care similar to abstinence-based counseling. Patients with buprenorphine plus counseling had reduced use of general medical services compared to the alternatives. BioMed Central 2014 2014-08-14 /pmc/articles/PMC4142137/ /pubmed/25123823 http://dx.doi.org/10.1186/1940-0640-9-16 Text en Copyright © 2014 Lynch et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Research
Lynch, Frances L
McCarty, Dennis
Mertens, Jennifer
Perrin, Nancy A
Green, Carla A
Parthasarathy, Sujaya
Dickerson, John F
Anderson, Bradley M
Pating, David
Costs of care for persons with opioid dependence in commercial integrated health systems
title Costs of care for persons with opioid dependence in commercial integrated health systems
title_full Costs of care for persons with opioid dependence in commercial integrated health systems
title_fullStr Costs of care for persons with opioid dependence in commercial integrated health systems
title_full_unstemmed Costs of care for persons with opioid dependence in commercial integrated health systems
title_short Costs of care for persons with opioid dependence in commercial integrated health systems
title_sort costs of care for persons with opioid dependence in commercial integrated health systems
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142137/
https://www.ncbi.nlm.nih.gov/pubmed/25123823
http://dx.doi.org/10.1186/1940-0640-9-16
work_keys_str_mv AT lynchfrancesl costsofcareforpersonswithopioiddependenceincommercialintegratedhealthsystems
AT mccartydennis costsofcareforpersonswithopioiddependenceincommercialintegratedhealthsystems
AT mertensjennifer costsofcareforpersonswithopioiddependenceincommercialintegratedhealthsystems
AT perrinnancya costsofcareforpersonswithopioiddependenceincommercialintegratedhealthsystems
AT greencarlaa costsofcareforpersonswithopioiddependenceincommercialintegratedhealthsystems
AT parthasarathysujaya costsofcareforpersonswithopioiddependenceincommercialintegratedhealthsystems
AT dickersonjohnf costsofcareforpersonswithopioiddependenceincommercialintegratedhealthsystems
AT andersonbradleym costsofcareforpersonswithopioiddependenceincommercialintegratedhealthsystems
AT patingdavid costsofcareforpersonswithopioiddependenceincommercialintegratedhealthsystems